Telix Doses First US Patients With FDA-Approved Brain Cancer Imaging Drug
MT Newswires Live
Oct 06
Telix Pharmaceuticals (TLX) said Tuesday it administered the first US doses of Pixclara, a Food and Drug Administration-approved positron emission tomography imaging drug for brain cancer imaging.
The initial doses took place at medical centers in Cleveland and Indianapolis, starting the product's commercial availability in the country, the company said.
PharmaLogic will be the manufacturing and pharmacy distribution partner to supply finished unit doses to the market, Telix said.
The drug, also known as floretyrosine F-18, is used to help differentiate recurrent or progressive glioma from treatment-related changes in patients aged one month and above, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.